Compare TDOC & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDOC | CMPS |
|---|---|---|
| Founded | 2002 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.2M | 778.7M |
| IPO Year | 2015 | 2020 |
| Metric | TDOC | CMPS |
|---|---|---|
| Price | $5.50 | $5.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | $7.59 | ★ $27.14 |
| AVG Volume (30 Days) | ★ 5.3M | 4.5M |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.58 | 0.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,406,840,000.00 | N/A |
| Revenue This Year | $1.74 | N/A |
| Revenue Next Year | $1.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.41 | N/A |
| 52 Week Low | $4.40 | $2.25 |
| 52 Week High | $9.77 | $8.90 |
| Indicator | TDOC | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 38.54 |
| Support Level | $4.44 | $4.78 |
| Resistance Level | $5.61 | $7.02 |
| Average True Range (ATR) | 0.22 | 0.44 |
| MACD | 0.09 | -0.14 |
| Stochastic Oscillator | 73.84 | 0.00 |
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with improved convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.